WO2002083175A1 - Agents ameliorant la fonction visuelle - Google Patents
Agents ameliorant la fonction visuelle Download PDFInfo
- Publication number
- WO2002083175A1 WO2002083175A1 PCT/JP2002/003590 JP0203590W WO02083175A1 WO 2002083175 A1 WO2002083175 A1 WO 2002083175A1 JP 0203590 W JP0203590 W JP 0203590W WO 02083175 A1 WO02083175 A1 WO 02083175A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- visual function
- improving agents
- function improving
- optic nerve
- promoting
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Ophthalmology & Optometry (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Emergency Medicine (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Priority Applications (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA2443918A CA2443918C (en) | 2001-04-11 | 2002-04-11 | Visual function disorder improving agents containing rho kinase inhibitors |
US10/474,369 US7109208B2 (en) | 2001-04-11 | 2002-04-11 | Visual function disorder improving agents |
EP02717107.3A EP1378247B1 (en) | 2001-04-11 | 2002-04-11 | Visual function disorder improving agents |
JP2002580976A JP4204326B2 (ja) | 2001-04-11 | 2002-04-11 | 視覚機能障害改善剤 |
KR1020037013344A KR100865262B1 (ko) | 2001-04-11 | 2002-04-11 | 시각 기능 장애 개선제 |
HK04109315.5A HK1066462A1 (en) | 2001-04-11 | 2004-11-25 | Visual function improving agents |
US11/366,460 US7696194B2 (en) | 2001-04-11 | 2006-03-03 | Visual function disorder improving agents |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2001113329 | 2001-04-11 | ||
JP2001-113329 | 2001-04-11 | ||
JP2001-308010 | 2001-10-03 | ||
JP2001308010 | 2001-10-03 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/366,460 Division US7696194B2 (en) | 2001-04-11 | 2006-03-03 | Visual function disorder improving agents |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2002083175A1 true WO2002083175A1 (fr) | 2002-10-24 |
Family
ID=26613462
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2002/003590 WO2002083175A1 (fr) | 2001-04-11 | 2002-04-11 | Agents ameliorant la fonction visuelle |
Country Status (8)
Country | Link |
---|---|
US (2) | US7109208B2 (ja) |
EP (1) | EP1378247B1 (ja) |
JP (2) | JP4204326B2 (ja) |
KR (2) | KR100883077B1 (ja) |
CN (2) | CN101310771B (ja) |
CA (2) | CA2707827A1 (ja) |
HK (1) | HK1066462A1 (ja) |
WO (1) | WO2002083175A1 (ja) |
Cited By (33)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003037308A2 (de) * | 2001-11-02 | 2003-05-08 | Morphochem Aktiengesellschaft für kombinatorische Chemie | Verwendung von inhibitoren der rho-kinasen zur stimulation des nervenwachstums |
WO2004091662A1 (ja) * | 2003-04-18 | 2004-10-28 | Senju Pharmaceutical Co. Ltd. | 角膜知覚回復剤 |
WO2005118582A1 (ja) | 2004-06-03 | 2005-12-15 | Senju Pharmaceutical Co., Ltd. | アミド化合物を含有する角膜知覚回復剤 |
WO2006112313A1 (ja) * | 2005-04-13 | 2006-10-26 | Ube Industries, Ltd. | インダゾール誘導体を有効成分として含む網膜神経細胞保護剤 |
WO2008016016A1 (en) | 2006-07-31 | 2008-02-07 | Senju Pharmaceutical Co., Ltd. | Aqueous liquid preparation containing amide compound |
WO2008105442A1 (ja) | 2007-02-28 | 2008-09-04 | Asahi Kasei Pharma Corporation | スルホンアミド誘導体 |
US7498342B2 (en) | 2004-06-17 | 2009-03-03 | Plexxikon, Inc. | Compounds modulating c-kit activity |
WO2009028631A1 (ja) | 2007-08-29 | 2009-03-05 | Senju Pharmaceutical Co., Ltd. | 角膜内皮細胞接着促進剤 |
WO2010010702A1 (ja) * | 2008-07-24 | 2010-01-28 | 国立大学法人大阪大学 | 軸性近視の予防または治療剤 |
US7846941B2 (en) | 2005-05-17 | 2010-12-07 | Plexxikon, Inc. | Compounds modulating c-kit and c-fms activity and uses therefor |
US7863288B2 (en) | 2005-06-22 | 2011-01-04 | Plexxikon, Inc. | Compounds and methods for kinase modulation, and indications therefor |
US7893075B2 (en) | 2006-11-22 | 2011-02-22 | Plexxikon, Inc. | Compounds modulating c-fms and/or c-kit activity and uses therefor |
WO2011081221A1 (en) | 2009-12-29 | 2011-07-07 | Senju Pharmaceutical Co., Ltd. | Therapeutic agent (y - 39983 ) for corneal endothelial dysfunction |
US8067434B2 (en) | 2003-12-19 | 2011-11-29 | Plexxikon Inc. | Compounds and methods for development of Ret modulators |
WO2013100208A1 (ja) | 2011-12-28 | 2013-07-04 | 京都府公立大学法人 | 角膜内皮細胞の培養正常化 |
US8865735B2 (en) | 2011-02-21 | 2014-10-21 | Hoffman-La Roche Inc. | Solid forms of a pharmaceutically active substance |
WO2014174747A1 (ja) | 2013-04-24 | 2014-10-30 | 国立大学法人九州大学 | 眼底疾患治療剤 |
WO2015016371A1 (ja) | 2013-07-30 | 2015-02-05 | 京都府公立大学法人 | 角膜内皮細胞マーカー |
WO2015029923A1 (ja) * | 2013-08-26 | 2015-03-05 | ロート製薬株式会社 | 眼科用製剤 |
WO2015064768A1 (ja) | 2013-10-31 | 2015-05-07 | 京都府公立大学法人 | 角膜内皮の小胞体細胞死関連疾患治療薬 |
WO2015080297A1 (en) | 2013-11-27 | 2015-06-04 | Kyoto Prefectural Public University Corporation | Application of laminin to corneal endothelial cell culture |
US9096593B2 (en) | 2009-11-06 | 2015-08-04 | Plexxikon Inc. | Compounds and methods for kinase modulation, and indications therefor |
US9138438B2 (en) | 2005-03-31 | 2015-09-22 | Asahi Glass Company, Limited | Method for protecting a retinal neuronal cell |
US9150570B2 (en) | 2012-05-31 | 2015-10-06 | Plexxikon Inc. | Synthesis of heterocyclic compounds |
JP2015229671A (ja) * | 2014-06-06 | 2015-12-21 | 株式会社デ・ウエスタン・セラピテクス研究所 | 網膜色素上皮細胞保護剤 |
US9447089B2 (en) | 2009-04-03 | 2016-09-20 | Plexxikon Inc. | Compositions and uses thereof |
US9469640B2 (en) | 2007-07-17 | 2016-10-18 | Plexxikon Inc. | Compounds and methods for kinase modulation, and indications therefor |
US9624213B2 (en) | 2011-02-07 | 2017-04-18 | Plexxikon Inc. | Compounds and methods for kinase modulation, and indications therefor |
WO2017141926A1 (en) | 2016-02-15 | 2017-08-24 | Kyoto Prefectural Public University Corporation | Human functional corneal endothelial cell and application thereof |
WO2020045642A1 (ja) | 2018-08-31 | 2020-03-05 | 学校法人同志社 | 眼細胞を保存または培養するための組成物および方法 |
WO2020071438A1 (ja) | 2018-10-02 | 2020-04-09 | 学校法人同志社 | 角膜内皮細胞を保存するための方法および容器 |
WO2021172554A1 (ja) | 2020-02-27 | 2021-09-02 | 京都府公立大学法人 | ヒト機能性角膜内皮細胞およびその応用 |
WO2023085369A1 (ja) | 2021-11-11 | 2023-05-19 | 学校法人同志社 | 角膜内皮細胞の凍結保存製剤およびその製造法 |
Families Citing this family (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004039366A1 (en) * | 2002-11-01 | 2004-05-13 | Pharmacia & Upjohn Company Llc | Nicotinic acetylcholine agonists in the treatment of glaucoma and retinal neuropathy |
WO2005034765A2 (en) * | 2003-10-03 | 2005-04-21 | Scimed Life Systems, Inc. | Systems for a delivering a medical implant to an anatomical location in a patient |
US20070014833A1 (en) * | 2005-03-30 | 2007-01-18 | Sirtris Pharmaceuticals, Inc. | Treatment of eye disorders with sirtuin modulators |
US20100022517A1 (en) * | 2006-12-18 | 2010-01-28 | Richards Lori A | Ophthalmic formulation of rho kinase inhibitor compound |
US8071779B2 (en) | 2006-12-18 | 2011-12-06 | Inspire Pharmaceuticals, Inc. | Cytoskeletal active rho kinase inhibitor compounds, composition and use |
US8895507B2 (en) * | 2007-04-16 | 2014-11-25 | The Board Of Trustees Of The Leland Stanford Junior University | Modulation of synaptogenesis |
GB0723825D0 (en) * | 2007-12-05 | 2008-01-23 | Ucl Business Plc | Composition |
US8273900B2 (en) | 2008-08-07 | 2012-09-25 | Novartis Ag | Organic compounds |
WO2010024903A1 (en) * | 2008-08-29 | 2010-03-04 | Yangbo Feng | BENZO[d]OXAZOLES AND BENZO[d]THIAZOLES AS KINASE INHIBITORS |
US8329724B2 (en) | 2009-08-03 | 2012-12-11 | Hoffmann-La Roche Inc. | Process for the manufacture of pharmaceutically active compounds |
JP2012006918A (ja) * | 2010-05-27 | 2012-01-12 | Santen Pharmaceut Co Ltd | イソキノリンスルホニル誘導体を有効成分として含有する網脈絡膜変性疾患の予防または治療剤 |
TW201202214A (en) * | 2010-05-27 | 2012-01-16 | Santen Pharmaceutical Co Ltd | Novel indazole derivative or salt thereof, production intermediate thereof, and prophylactic or therapeutic agent for chorioretinal degeneratire disease using the same |
RU2452436C1 (ru) * | 2011-01-31 | 2012-06-10 | Федеральное государственное учреждение "Межотраслевой научно-технический комплекс "Микрохирургия глаза" имени академика С.Н. Федорова Федерального агентства по высокотехнологичной медицинской помощи" | Способ лечения атрофии зрительного нерва сосудистого генеза |
CA2859832C (en) * | 2011-12-20 | 2015-07-14 | Research Foundation Of The City University Of New York | Method for screening a drug in retinal tissue |
CA2965770C (en) | 2014-10-31 | 2024-02-13 | Kyoto Prefectural Public University Corporation | Treatment of cornea using laminin |
US11918630B2 (en) | 2014-10-31 | 2024-03-05 | Kyoto Prefectural Public University Corporation | Treatment of retina and nerve using laminin |
EP4088719A1 (en) * | 2015-10-13 | 2022-11-16 | Institut National de la Santé et de la Recherche Médicale (INSERM) | Methods and pharmaceutical compositions for the treatment of retinal capillary non-perfusion |
WO2017064119A1 (en) * | 2015-10-13 | 2017-04-20 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for the treatment of retinal capillary non-perfusion |
WO2018041824A1 (en) * | 2016-08-29 | 2018-03-08 | Amneal Pharmaceuticals Company Gmbh | Stable pharmaceutical composition of ethacrynic acid |
MA52813A (fr) * | 2018-06-07 | 2021-04-14 | Disarm Therapeutics Inc | Inhibiteurs de sarm1 |
EP3801503A4 (en) * | 2018-06-07 | 2021-12-08 | Disarm Therapeutics, Inc. | INHIBITORS OF SARM1 |
EP3801499B1 (en) * | 2018-06-07 | 2024-02-28 | Disarm Therapeutics, Inc. | Inhibitors of sarm1 |
US20220242859A1 (en) * | 2019-06-06 | 2022-08-04 | Disarm Therapeutics, Inc. | Inhibitors of sarm1 |
KR20230027186A (ko) * | 2020-06-19 | 2023-02-27 | 엔도제나 테라퓨틱스, 인코포레이티드 | 새로운 화합물 및 망막 색소 상피와 관련된 질병의 치료 및/또는 예방에서 치료적 활성 물질로서의 이들의 용도 |
Citations (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0609822A1 (en) * | 1993-02-02 | 1994-08-10 | Takeda Chemical Industries, Ltd. | Pharmaceutical composition for preventing and treating retinal diseases |
EP0728480A1 (en) * | 1995-02-24 | 1996-08-28 | Rohto Pharmaceutical Co., Ltd. | Use of ifenprodil for treatment of elevated intraocular pressure |
WO1997019694A1 (en) * | 1995-11-29 | 1997-06-05 | Amgen Inc. | Methods for treating photoreceptors using glial cell line-derived neurotrophic factor (gdnf) protein product |
WO1998006433A1 (fr) * | 1996-08-12 | 1998-02-19 | Yoshitomi Pharmaceutical Industries, Ltd. | MEDICAMENTS COMPRENANT UN INHIBITEUR DE LA Rho KINASE |
JPH10113187A (ja) * | 1995-11-20 | 1998-05-06 | Kirin Brewery Co Ltd | Rho標的タンパク質Rhoキナーゼ |
JPH10201480A (ja) * | 1996-07-24 | 1998-08-04 | Kirin Brewery Co Ltd | ヒト由来のRho標的タンパク質Rhoキナーゼおよびその遺伝子 |
WO1998034485A1 (en) * | 1997-02-12 | 1998-08-13 | Layton Bioscience, Inc. | METHOD OF TREATING BLINDNESS WITH hNT HUMAN NEURONAL CELLS |
WO1999000133A1 (en) * | 1997-06-26 | 1999-01-07 | Merck & Co., Inc. | Method for optimizing retinal and optic nerve health |
WO1999023113A2 (en) * | 1997-10-31 | 1999-05-14 | Lisa Mckerracher | Rho family antagonists and their use to block inhibition of neurite outgrowth |
EP1034793A1 (en) * | 1998-08-17 | 2000-09-13 | Senju Pharmaceutical Co., Ltd. | Preventives/remedies for glaucoma |
WO2000057914A1 (fr) * | 1999-03-25 | 2000-10-05 | Santen Pharmaceutical Co., Ltd. | Agents permettant d'abaisser la tension oculaire |
EP1064944A1 (en) * | 1999-06-25 | 2001-01-03 | Schering Aktiengesellschaft | Protein kinase N inhibitor comprising Fasudil |
JP2001081048A (ja) * | 1999-09-10 | 2001-03-27 | Wakamoto Pharmaceut Co Ltd | 眼圧降下剤 |
Family Cites Families (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4456757A (en) | 1981-03-20 | 1984-06-26 | Asahi Kasei Kogyo Kabushiki Kaisha | Isoquinolinesulfonyl derivatives and process for the preparation thereof |
US4678783B1 (en) | 1983-11-04 | 1995-04-04 | Asahi Chemical Ind | Substituted isoquinolinesulfonyl compounds |
JPH0680054B2 (ja) | 1985-06-19 | 1994-10-12 | 吉富製薬株式会社 | ピペリジン誘導体 |
JP2770497B2 (ja) | 1988-11-24 | 1998-07-02 | 吉富製薬株式会社 | トランス―4―アミノ(アルキル)―1―ピリジルカルバモイルシクロヘキサン化合物およびその医薬用途 |
JP2720348B2 (ja) | 1989-03-30 | 1998-03-04 | 旭化成工業株式会社 | 脳細胞機能障害改善剤 |
JP3408546B2 (ja) | 1991-02-19 | 2003-05-19 | 旭化成株式会社 | 抗喘息剤 |
JP2864489B2 (ja) | 1991-02-27 | 1999-03-03 | 吉富製薬株式会社 | 喘息治療剤 |
DK0641781T3 (da) | 1991-09-06 | 2000-09-18 | Yoshitomi Pharmaceutical | 4-Amino(alkyl)cyclohexan-1-carboxamidforbindelser og anvendelse af disse |
JP3265695B2 (ja) | 1992-05-12 | 2002-03-11 | 三菱ウェルファーマ株式会社 | 4−置換アミノ(アルキル)シクロヘキサン−1−カルボン酸アミド化合物 |
JP2893029B2 (ja) | 1992-08-10 | 1999-05-17 | 旭化成工業株式会社 | 心臓保護剤 |
JPH0680569A (ja) | 1992-09-03 | 1994-03-22 | Asahi Chem Ind Co Ltd | 血小板凝集阻害剤 |
JP3218356B2 (ja) | 1993-03-31 | 2001-10-15 | ヤンマー農機株式会社 | 管理機 |
JP3464012B2 (ja) | 1993-04-05 | 2003-11-05 | 旭化成株式会社 | 精神症候治療剤 |
JPH0741424A (ja) | 1993-07-28 | 1995-02-10 | Asahi Chem Ind Co Ltd | 抗炎症剤 |
JPH07277979A (ja) | 1994-04-12 | 1995-10-24 | Asahi Chem Ind Co Ltd | 過粘性症候群治療または予防剤 |
EP1195372A1 (en) | 1994-04-18 | 2002-04-10 | Mitsubishi Pharma Corporation | N-heterocyclic substituted benzamide derivatives with antihypertensive activity |
US5906819A (en) | 1995-11-20 | 1999-05-25 | Kirin Beer Kabushiki Kaisha | Rho target protein Rho-kinase |
DE69634414T2 (de) | 1995-12-21 | 2005-11-17 | Alcon Laboratories, Inc., Fort Worth | Verwendung von substituierten isochinolinsulfonyl-verbindungen zur herstellung eines medikaments für die behandlung von glaukom und okularer ischämie |
CA2240271C (en) | 1995-12-21 | 2005-12-13 | Alcon Laboratories, Inc. | Use of certain isoquinolinesulfonyl compounds for the treatment of glaucoma and ocular ischemia |
DE69724108T2 (de) | 1996-02-02 | 2004-06-09 | D.Western Therapeutics Institute, Nagoya | Isochinolinderivate und arzneimittel |
JPH09227381A (ja) | 1996-02-29 | 1997-09-02 | Asahi Chem Ind Co Ltd | 脳血栓における運動麻痺の改善剤 |
US5733904A (en) | 1996-04-10 | 1998-03-31 | Asahi Kasei Kogyo Kabushiki Kaisha | Method for prevention and treatment of viral infectious diseases for viral suppression |
JPH1087491A (ja) | 1996-07-26 | 1998-04-07 | Asahi Chem Ind Co Ltd | 転写調節因子阻害剤 |
WO1999061403A1 (fr) | 1998-05-25 | 1999-12-02 | Santen Pharmaceutical Co., Ltd. | Nouveaux derives vinylbenzene |
US7217722B2 (en) | 2000-02-01 | 2007-05-15 | Kirin Beer Kabushiki Kaisha | Nitrogen-containing compounds having kinase inhibitory activity and drugs containing the same |
EP1270570B1 (en) * | 2000-03-16 | 2006-05-31 | Mitsubishi Pharma Corporation | Amide compounds and use thereof |
JP4273821B2 (ja) | 2003-04-21 | 2009-06-03 | ヤマハ株式会社 | 音声データ処理プログラム |
JP4264030B2 (ja) | 2003-06-04 | 2009-05-13 | 株式会社ケンウッド | 音声データ選択装置、音声データ選択方法及びプログラム |
-
2002
- 2002-04-11 CA CA2707827A patent/CA2707827A1/en not_active Abandoned
- 2002-04-11 KR KR1020087011955A patent/KR100883077B1/ko not_active IP Right Cessation
- 2002-04-11 JP JP2002580976A patent/JP4204326B2/ja not_active Expired - Fee Related
- 2002-04-11 US US10/474,369 patent/US7109208B2/en not_active Expired - Fee Related
- 2002-04-11 KR KR1020037013344A patent/KR100865262B1/ko not_active IP Right Cessation
- 2002-04-11 CA CA2443918A patent/CA2443918C/en not_active Expired - Fee Related
- 2002-04-11 CN CN2008101357171A patent/CN101310771B/zh not_active Expired - Fee Related
- 2002-04-11 CN CNB028080416A patent/CN100411686C/zh not_active Expired - Fee Related
- 2002-04-11 EP EP02717107.3A patent/EP1378247B1/en not_active Expired - Lifetime
- 2002-04-11 WO PCT/JP2002/003590 patent/WO2002083175A1/ja active Application Filing
-
2004
- 2004-11-25 HK HK04109315.5A patent/HK1066462A1/xx not_active IP Right Cessation
-
2006
- 2006-03-03 US US11/366,460 patent/US7696194B2/en not_active Expired - Fee Related
-
2008
- 2008-05-16 JP JP2008130147A patent/JP4802211B2/ja not_active Expired - Fee Related
Patent Citations (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0609822A1 (en) * | 1993-02-02 | 1994-08-10 | Takeda Chemical Industries, Ltd. | Pharmaceutical composition for preventing and treating retinal diseases |
EP0728480A1 (en) * | 1995-02-24 | 1996-08-28 | Rohto Pharmaceutical Co., Ltd. | Use of ifenprodil for treatment of elevated intraocular pressure |
JPH10113187A (ja) * | 1995-11-20 | 1998-05-06 | Kirin Brewery Co Ltd | Rho標的タンパク質Rhoキナーゼ |
WO1997019694A1 (en) * | 1995-11-29 | 1997-06-05 | Amgen Inc. | Methods for treating photoreceptors using glial cell line-derived neurotrophic factor (gdnf) protein product |
JPH10201480A (ja) * | 1996-07-24 | 1998-08-04 | Kirin Brewery Co Ltd | ヒト由来のRho標的タンパク質Rhoキナーゼおよびその遺伝子 |
WO1998006433A1 (fr) * | 1996-08-12 | 1998-02-19 | Yoshitomi Pharmaceutical Industries, Ltd. | MEDICAMENTS COMPRENANT UN INHIBITEUR DE LA Rho KINASE |
WO1998034485A1 (en) * | 1997-02-12 | 1998-08-13 | Layton Bioscience, Inc. | METHOD OF TREATING BLINDNESS WITH hNT HUMAN NEURONAL CELLS |
WO1999000133A1 (en) * | 1997-06-26 | 1999-01-07 | Merck & Co., Inc. | Method for optimizing retinal and optic nerve health |
WO1999023113A2 (en) * | 1997-10-31 | 1999-05-14 | Lisa Mckerracher | Rho family antagonists and their use to block inhibition of neurite outgrowth |
EP1034793A1 (en) * | 1998-08-17 | 2000-09-13 | Senju Pharmaceutical Co., Ltd. | Preventives/remedies for glaucoma |
WO2000057914A1 (fr) * | 1999-03-25 | 2000-10-05 | Santen Pharmaceutical Co., Ltd. | Agents permettant d'abaisser la tension oculaire |
EP1064944A1 (en) * | 1999-06-25 | 2001-01-03 | Schering Aktiengesellschaft | Protein kinase N inhibitor comprising Fasudil |
JP2001081048A (ja) * | 1999-09-10 | 2001-03-27 | Wakamoto Pharmaceut Co Ltd | 眼圧降下剤 |
Non-Patent Citations (5)
Title |
---|
BITO H. ET AL.: "A critical role for a rho-associated kinase, p16ROCK, in determining axon outgrowth in mammalian CNS neurons", NEURON, vol. 26, no. 2, 2000, pages 431 - 441, XP002952685 * |
HIROSE, M. ET AL.: "Molecular dissection of the rho-associated protein kinase (p160ROCK)-regulated neurite remodeling in neuroblastoma N1E-115 cells", J. CELL BIOL., vol. 141, no. 7, 1998, pages 1625 - 1636, XP002952683 * |
LEHMANN, M. ET AL.: "Inactivation of rho signaling pathway promotes CNS axon regeneration", J. NEUROSCI., vol. 19, no. 17, 1999, pages 7537 - 7547, XP002952684 * |
MCKERRACHER, L.: "Strategies to promote regeneration of adult rat retinal ganglion cell axons in the nerve", vol. 4, no. 2/3, 1 September 2001 (2001-09-01), pages 253(S47-6), XP002952686 * |
See also references of EP1378247A4 * |
Cited By (68)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003037308A2 (de) * | 2001-11-02 | 2003-05-08 | Morphochem Aktiengesellschaft für kombinatorische Chemie | Verwendung von inhibitoren der rho-kinasen zur stimulation des nervenwachstums |
WO2003037308A3 (de) * | 2001-11-02 | 2003-09-18 | Morphochem Ag Komb Chemie | Verwendung von inhibitoren der rho-kinasen zur stimulation des nervenwachstums |
WO2004091662A1 (ja) * | 2003-04-18 | 2004-10-28 | Senju Pharmaceutical Co. Ltd. | 角膜知覚回復剤 |
KR101076638B1 (ko) * | 2003-04-18 | 2011-10-27 | 센주 세이야꾸 가부시키가이샤 | 각막 지각 회복제 |
JPWO2004091662A1 (ja) * | 2003-04-18 | 2006-07-06 | 千寿製薬株式会社 | 角膜知覚回復剤 |
JP4566130B2 (ja) * | 2003-04-18 | 2010-10-20 | 千寿製薬株式会社 | 角膜知覚回復剤 |
US8067434B2 (en) | 2003-12-19 | 2011-11-29 | Plexxikon Inc. | Compounds and methods for development of Ret modulators |
JPWO2005118582A1 (ja) * | 2004-06-03 | 2008-04-03 | 千寿製薬株式会社 | アミド化合物を含有する角膜知覚回復剤 |
JP4932480B2 (ja) * | 2004-06-03 | 2012-05-16 | 千寿製薬株式会社 | アミド化合物を含有する角膜知覚回復剤 |
WO2005118582A1 (ja) | 2004-06-03 | 2005-12-15 | Senju Pharmaceutical Co., Ltd. | アミド化合物を含有する角膜知覚回復剤 |
US7498342B2 (en) | 2004-06-17 | 2009-03-03 | Plexxikon, Inc. | Compounds modulating c-kit activity |
US7947708B2 (en) | 2004-06-17 | 2011-05-24 | Plexxikon, Inc. | Compounds modulating C-kit activity |
US9138438B2 (en) | 2005-03-31 | 2015-09-22 | Asahi Glass Company, Limited | Method for protecting a retinal neuronal cell |
US8252945B2 (en) | 2005-04-13 | 2012-08-28 | Ube Industries, Ltd. | Protective agent for retinal neuronal cell comprising indazole derivative as active ingredient |
JPWO2006112313A1 (ja) * | 2005-04-13 | 2008-12-11 | 宇部興産株式会社 | インダゾール誘導体を有効成分として含む網膜神経細胞保護剤 |
WO2006112313A1 (ja) * | 2005-04-13 | 2006-10-26 | Ube Industries, Ltd. | インダゾール誘導体を有効成分として含む網膜神経細胞保護剤 |
US7846941B2 (en) | 2005-05-17 | 2010-12-07 | Plexxikon, Inc. | Compounds modulating c-kit and c-fms activity and uses therefor |
US7863288B2 (en) | 2005-06-22 | 2011-01-04 | Plexxikon, Inc. | Compounds and methods for kinase modulation, and indications therefor |
WO2008016016A1 (en) | 2006-07-31 | 2008-02-07 | Senju Pharmaceutical Co., Ltd. | Aqueous liquid preparation containing amide compound |
JPWO2008016016A1 (ja) * | 2006-07-31 | 2009-12-24 | 千寿製薬株式会社 | アミド化合物を含有する水性液剤 |
US9487515B2 (en) | 2006-11-22 | 2016-11-08 | Plexxikon Inc. | Compounds modulating c-fms and/or c-kit activity and uses therefor |
US7893075B2 (en) | 2006-11-22 | 2011-02-22 | Plexxikon, Inc. | Compounds modulating c-fms and/or c-kit activity and uses therefor |
US9169250B2 (en) | 2006-11-22 | 2015-10-27 | Plexxikon Inc. | Compounds modulating c-fms and/or c-kit activity and uses therefor |
WO2008105442A1 (ja) | 2007-02-28 | 2008-09-04 | Asahi Kasei Pharma Corporation | スルホンアミド誘導体 |
US9844539B2 (en) | 2007-07-17 | 2017-12-19 | Plexxikon Inc. | Compounds and methods for kinase modulation, and indications therefor |
US9469640B2 (en) | 2007-07-17 | 2016-10-18 | Plexxikon Inc. | Compounds and methods for kinase modulation, and indications therefor |
US10426760B2 (en) | 2007-07-17 | 2019-10-01 | Plexxikon Inc. | Compounds and methods for kinase modulation, and indications therefor |
KR20190091567A (ko) | 2007-08-29 | 2019-08-06 | 센주 세이야꾸 가부시키가이샤 | 각막 내피 세포 접착 촉진제 |
US9248125B2 (en) | 2007-08-29 | 2016-02-02 | Senju Pharmaceutical Co., Ltd. | Agent for promoting corneal endothelial cell adhesion |
KR20210070407A (ko) | 2007-08-29 | 2021-06-14 | 센주 세이야꾸 가부시키가이샤 | 각막 내피 세포 접착 촉진제 |
WO2009028631A1 (ja) | 2007-08-29 | 2009-03-05 | Senju Pharmaceutical Co., Ltd. | 角膜内皮細胞接着促進剤 |
KR20240045364A (ko) | 2007-08-29 | 2024-04-05 | 센주 세이야꾸 가부시키가이샤 | 각막 내피 세포 접착 촉진제 |
US11839618B2 (en) | 2007-08-29 | 2023-12-12 | Senju Pharmaceutical Co., Ltd. | Agent for promoting corneal endothelial cell adhesion |
KR20220151013A (ko) | 2007-08-29 | 2022-11-11 | 센주 세이야꾸 가부시키가이샤 | 각막 내피 세포 접착 촉진제 |
US11633404B2 (en) | 2007-08-29 | 2023-04-25 | Senju Pharmaceutical Co., Ltd. | Agent for promoting corneal endothelial cell adhesion |
WO2010010702A1 (ja) * | 2008-07-24 | 2010-01-28 | 国立大学法人大阪大学 | 軸性近視の予防または治療剤 |
JPWO2010010702A1 (ja) * | 2008-07-24 | 2012-01-05 | 国立大学法人大阪大学 | 軸性近視の予防または治療剤 |
US9663517B2 (en) | 2009-04-03 | 2017-05-30 | Plexxikon Inc. | Compositions and uses thereof |
US9447089B2 (en) | 2009-04-03 | 2016-09-20 | Plexxikon Inc. | Compositions and uses thereof |
US9096593B2 (en) | 2009-11-06 | 2015-08-04 | Plexxikon Inc. | Compounds and methods for kinase modulation, and indications therefor |
JP2015155460A (ja) * | 2009-12-29 | 2015-08-27 | 千寿製薬株式会社 | 角膜内皮障害治療剤(y−39983) |
WO2011080984A1 (en) | 2009-12-29 | 2011-07-07 | Senju Pharmaceutical Co., Ltd. | Therapeutic agent (y - 39983 ) for corneal endothelial dysfunction |
JP2013515676A (ja) * | 2009-12-29 | 2013-05-09 | 千寿製薬株式会社 | 角膜内皮障害治療剤(y−39983) |
WO2011081221A1 (en) | 2009-12-29 | 2011-07-07 | Senju Pharmaceutical Co., Ltd. | Therapeutic agent (y - 39983 ) for corneal endothelial dysfunction |
US9624213B2 (en) | 2011-02-07 | 2017-04-18 | Plexxikon Inc. | Compounds and methods for kinase modulation, and indications therefor |
US11337976B2 (en) | 2011-02-07 | 2022-05-24 | Plexxikon Inc. | Compounds and methods for kinase modulation, and indications therefor |
US8865735B2 (en) | 2011-02-21 | 2014-10-21 | Hoffman-La Roche Inc. | Solid forms of a pharmaceutically active substance |
EP3553169A1 (en) | 2011-12-28 | 2019-10-16 | Kyoto Prefectural Public University Corporation | Normalization of culture of corneal endothelial cells |
WO2013100208A1 (ja) | 2011-12-28 | 2013-07-04 | 京都府公立大学法人 | 角膜内皮細胞の培養正常化 |
US9695169B2 (en) | 2012-05-31 | 2017-07-04 | Plexxikon Inc. | Synthesis of heterocyclic compounds |
US9150570B2 (en) | 2012-05-31 | 2015-10-06 | Plexxikon Inc. | Synthesis of heterocyclic compounds |
KR20150145229A (ko) | 2013-04-24 | 2015-12-29 | 고쿠리쓰다이가쿠호진 규슈다이가쿠 | 안저질환 치료제 |
US10426783B2 (en) | 2013-04-24 | 2019-10-01 | Kyushu University, Nat'l University Corporation | Therapeutic agent for ocular fundus disease |
EP3626245A1 (en) | 2013-04-24 | 2020-03-25 | Kyushu University, National University Corporation | Therapeutic agent for eyeground disease |
WO2014174747A1 (ja) | 2013-04-24 | 2014-10-30 | 国立大学法人九州大学 | 眼底疾患治療剤 |
WO2015016371A1 (ja) | 2013-07-30 | 2015-02-05 | 京都府公立大学法人 | 角膜内皮細胞マーカー |
US10908161B2 (en) | 2013-07-30 | 2021-02-02 | Kyoto Prefectural Public University Corporation | Corneal endothelial cell marker |
WO2015029923A1 (ja) * | 2013-08-26 | 2015-03-05 | ロート製薬株式会社 | 眼科用製剤 |
EP3804760A1 (en) | 2013-10-31 | 2021-04-14 | Kyoto Prefectural Public University Corporation | Therapeutic drug for diseases related to endoplasmic reticulum cell death in corneal endothelium |
WO2015064768A1 (ja) | 2013-10-31 | 2015-05-07 | 京都府公立大学法人 | 角膜内皮の小胞体細胞死関連疾患治療薬 |
WO2015080297A1 (en) | 2013-11-27 | 2015-06-04 | Kyoto Prefectural Public University Corporation | Application of laminin to corneal endothelial cell culture |
JP2015229671A (ja) * | 2014-06-06 | 2015-12-21 | 株式会社デ・ウエスタン・セラピテクス研究所 | 網膜色素上皮細胞保護剤 |
WO2017141926A1 (en) | 2016-02-15 | 2017-08-24 | Kyoto Prefectural Public University Corporation | Human functional corneal endothelial cell and application thereof |
EP4218773A1 (en) | 2016-02-15 | 2023-08-02 | Kyoto Prefectural Public University Corporation | Human functional corneal endothelial cell and application thereof |
WO2020045642A1 (ja) | 2018-08-31 | 2020-03-05 | 学校法人同志社 | 眼細胞を保存または培養するための組成物および方法 |
WO2020071438A1 (ja) | 2018-10-02 | 2020-04-09 | 学校法人同志社 | 角膜内皮細胞を保存するための方法および容器 |
WO2021172554A1 (ja) | 2020-02-27 | 2021-09-02 | 京都府公立大学法人 | ヒト機能性角膜内皮細胞およびその応用 |
WO2023085369A1 (ja) | 2021-11-11 | 2023-05-19 | 学校法人同志社 | 角膜内皮細胞の凍結保存製剤およびその製造法 |
Also Published As
Publication number | Publication date |
---|---|
CA2443918C (en) | 2012-06-05 |
CN101310771A (zh) | 2008-11-26 |
CN101310771B (zh) | 2012-08-08 |
EP1378247A1 (en) | 2004-01-07 |
EP1378247A8 (en) | 2004-12-22 |
EP1378247B1 (en) | 2016-08-24 |
JP2008247923A (ja) | 2008-10-16 |
US20060148852A1 (en) | 2006-07-06 |
KR20080047633A (ko) | 2008-05-29 |
EP1378247A4 (en) | 2007-07-25 |
CN1501813A (zh) | 2004-06-02 |
JP4802211B2 (ja) | 2011-10-26 |
US7696194B2 (en) | 2010-04-13 |
CA2443918A1 (en) | 2002-10-24 |
US7109208B2 (en) | 2006-09-19 |
US20040106646A1 (en) | 2004-06-03 |
CA2707827A1 (en) | 2002-10-24 |
KR20040007495A (ko) | 2004-01-24 |
KR100883077B1 (ko) | 2009-02-10 |
CN100411686C (zh) | 2008-08-20 |
HK1066462A1 (en) | 2005-03-24 |
JPWO2002083175A1 (ja) | 2004-08-05 |
JP4204326B2 (ja) | 2009-01-07 |
KR100865262B1 (ko) | 2008-10-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2002083175A1 (fr) | Agents ameliorant la fonction visuelle | |
EA200800337A1 (ru) | Композиция и способ введения офтальмологически активных средств | |
PL396553A1 (pl) | Zastosowanie czynnika do wytwarzania leku do leczenia jaskry | |
WO2007011874A3 (en) | Formulation and method for administration of ophthalmologically active agents | |
WO2005118609A3 (en) | Small molecule stimulators of neuronal growth | |
NO20060113L (no) | Pyrrolo(3,4-c)pyrazolderivater aktive som kinase inhibitorer | |
WO2006004703A3 (en) | PYRROLO[2,3-d]PYRIMIDINES THAT MODULATE ACK1 AND LCK ACTIVITY | |
WO2005069865A3 (en) | Pyrrolopyrimidine derivatives and analogs and their use in the treatment and prevention of diseases | |
WO2001087328A3 (en) | Interleukin-1 inhibitors in the treatment of diseases | |
BR0315645A (pt) | Polipetìdeos de fusão de actrib e seus usos | |
CA2361834A1 (en) | Offset ablation profiles for treatment of irregular astigmatism | |
WO2004089471A3 (en) | NEW PYRAZOLO[1,5-a] PYRIMIDINES DERIVATIVES AND PHARMACEUTICAL USE THEREOF | |
ES2044829T3 (es) | Metodo y composiciones para la inhibicion de alteraciones asociadas con las lesiones oxidativas de los tejidos. | |
CA2251982A1 (en) | Ophthalmic compound with extended dwell time on the eye | |
BR0210241A (pt) | Piranoindazóis e seu uso no tratamento de glaucoma | |
WO2002090332A3 (en) | Novel aeylheteroalkylaminε derivatives | |
NZ505742A (en) | Compositions containing aminobiguanides with antimicrobial activity used to treat contact lenses | |
WO2001068053A3 (en) | Methods and compositions for treating and preventing posterior segment ophthalmic disorders | |
WO2000018316A3 (en) | Sustained release, and comfortable ophthalmic composition and method for ocular therapy | |
CA2506464A1 (en) | Therapeutic agent for glaucoma comprising rho kinase inhibitor and .beta.-blocker | |
EP2354155A3 (en) | Fusion Proteins for Treatment of CNS | |
WO2002067971A3 (en) | Use of endostatin in the treatment of ocular neovascularization | |
BR0313425A (pt) | Composição oftálmica para tratamento de alergia ocular, uso do composto de macrolìdeo e pacote comercial | |
WO2003061519A3 (en) | Methods and compositions for preserving the viability of photoreceptor cells | |
NO20001934L (no) | 3-Substituerte tetrahydropyridopyrimidinon-derivater, deres fremstilling og anvendelse |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2002580976 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 028080416 Country of ref document: CN Ref document number: 1020037013344 Country of ref document: KR |
|
REEP | Request for entry into the european phase |
Ref document number: 2002717107 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2002717107 Country of ref document: EP Ref document number: 2443918 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 10474369 Country of ref document: US |
|
WWP | Wipo information: published in national office |
Ref document number: 2002717107 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |